Ampio Pharmaceuticals, Inc. (AMPE) Social Stream



Ampio Pharmaceuticals, Inc. (AMPE): $0.92

0.10 (+12.20%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add AMPE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#285 of 357

in industry

AMPIO PHARMACEUTICALS INC (AMPE) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering AMPE.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-03-03 1 $4 $4 $4 $2.09 91.39%
2022-04-22 1 $4 $3 $3.5 $2.09 67.46%
2022-05-18 1 $3 $2 $2.5 $2.09 19.62%

Price Target Last Issued April 22, 2022

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential

AMPE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

The Trend in the Broker Recommendations


AMPE's average broker recommendation rating improved by 0 over the prior 30 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, AMPIO PHARMACEUTICALS INC's number of analysts covering the stock is higher than nearly none of them.
  • AMPIO PHARMACEUTICALS INC's average analyst price target is greater than 5.94% of all US stocks.
  • AMPIO PHARMACEUTICALS INC's variance in analysts' estimates is lower than 61.51% of Pharmaceutical Products stocks.
  • AMPIO PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is higher than 106.63% of Pharmaceutical Products stocks.

In the Pharmaceutical Products industry, VTGN, CRMD, and MDVL are the three stocks most similar to AMPIO PHARMACEUTICALS INC regarding the price target and analyst recommendation information presented here.

Is AMPE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!